🔗 Share this article

Given that the United States undertakes sweeping adjustments to its vaccine recommendations, an unexpected name has emerged somewhat surprisingly: Høeg, a US-based sports medicine doctor and public health researcher who initially gained attention by questioning Covid vaccines throughout the global health crisis and has focused upon potential deaths after Covid immunization in her short position at the US Food and Drug Administration (FDA).

Planned Shifts to Pediatric Vaccine Schedule

Public health authorities had intended to reveal major changes to the pediatric immunization program recently, bringing the US with Denmark’s national calendar, it is understood – a major change that would place the US out of step with many the international standard with little proof for benefit. The announcement has been delayed until the coming year.

In place of the director of the vaccine center, Høeg is listed to speak at the gathering. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the division this year.

Consolidating Power at the Agency

Høeg's temporary position could signify a tighter collaboration between the pharmaceutical and vaccine branches as Dr. Høeg and Prasad consolidate power at the FDA – and it signals a greater focus upon dismantling long-standing vaccines at the FDA.

Høeg has often pushed for halting specific pediatric shot schedules in the US so as to align more like Denmark, a society with nationalized medicine and a citizenry approximately the population of the state of Wisconsin.

So far statements, she has continued to focus on vaccines – traditionally the purview of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to pharmaceutical oversight.

Concerns Over Qualifications

Dr. Høeg has no apparent background in pharmaceutical research, regulation or administrative roles, which has been typical for past directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the agency head and CBER since earlier this year.

“She doesn’t seem to have the requisite experience” for overseeing the pharmaceutical oversight division, stated Dr. Jonathan Howard. “She lacks experience running a randomized controlled trial. She lacks experience in leading a large organization. She is not an expert in industry regulation.”

Previous directors of the center would “grasp legal statutes and the science of pharmaceutical innovation”, commented Janet Woodcock. “Clearly, she lacks the type of experience that prior appointees who ran CBER have had.”

CDER has an enormous workload at the agency, she pointed out.

“The public just focuses on the novel medication approvals, but the generic drug division approves a multitude of off-brand pharmaceuticals. There’s a biosimilars program, non-prescription drug unit and other areas, and every single one have to be managed,” she said. “The area you overlook, that is the part that I always told people is going to come back to haunt you.”

There is also, a substantial administrative element to the job, which supervises more than 5,000 personnel. “It’s a enormous leadership role, if you execute it properly,” Woodcock added.

Agency Reaction and Disputed Programs

Regarding questions about Høeg’s qualifications and whether this selection signifies increased cooperation among FDA leaders on immunizations, a spokesperson responded that the “concerns stem from flawed assumptions”.

“Her experience is consistent with the responsibilities of her position,” the official said, noting the months Høeg spent guiding the FDA commissioner on “drug safety and approval science, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Dr. Høeg assumes responsibility for the commissioner’s new expedited review system, a contentious rapid therapy clearance system that reportedly troubled her predecessors. “How are these therapies being picked for this voucher program? Who is making the decisions?” Howard asked. “There’s a lot of confidentiality occurring at the agency right now.”

Overall, he remarked, “the agency looks to be trending towards less stringent oversight of all drugs, with the exception of immunizations.”

Public Past Work on Vaccines

Regarding vaccines, Høeg has a clearer, if concerning, track record, some experts said. She published a analysis using unconfirmed volunteer-provided data to assess the incidence of heart inflammation after COVID-19 immunization. She advised the Florida surgeon general Dr. Joseph Ladapo, who allegedly have altered data to imply COVID-19 vaccines are riskier than they are.

Included in her “wish list” for the current administration featured revising rules for novel immunizations and halting “unnecessary” immunizations, she remarked after the election on a audio program. At the FDA, Dr. Høeg has according to sources floated the idea of preventing young men from getting COVID-19 vaccinations.

“She’s an complete true believer who commences with her preconceived notions and tailors the evidence to accommodate the evidence in a extremely deceptive, fraudulent fashion,” Howard argued.

Taking Control and a “Campaign of Retribution”

Dr. Høeg became part of fellow contrarians, {like|